|
|
May/June 2008 Continuous Quality Verification Process is Subject of New Pharmaceutical Standard
“Continuous quality verification is an alternative process validation approach whereby the desired quality attributes are ensured through continuous assessment during manufacture,” says Graham Wrigley, E55 member and senior manager, PGM Global Quality Operations Center, Pfizer Inc. “The adoption of this quality approach will move us from the documentation of a discreet process validation exercise to a science-based systematic approach. With the knowledge obtained during the product life cycle, a number of benefits may be afforded, for example, real-time release and continuous quality improvement.” The purpose of E2537 is to address the application of continuous quality verification to those manufacturing processes that employ modern quality management systems often supplemented with modern process analytical chemistry systems and controls. Pharmaceutical manufacturers that have batch or continuous processes that employ analyzers and controllers that monitor and measure, as well as analyze and control the process performance, will be the primary users of the standard. Interested parties are welcome to participate in future work on E2537, particularly those involved in pharmaceutical and biopharmaceutical manufacturing, research and development, and process analytical technologies. “As the industry moves to implementing continuous quality verification, input will be needed again to review and revise the standard based on practical experience,” says Wrigley. CONTACT Technical Information: Graham Wrigley, Pfizer Global Manufacturing, Peapack, N.J. Phone: 908/901-8830 ASTM Staff: Pat Picariello Phone: 610/832-9720
|